A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Fate Therapeutics
Related studies linked through entity extraction aliases.
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
- Status
- RECRUITING
- Phase
- PHASE1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Status
- RECRUITING
- Phase
- PHASE1
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
- Status
- COMPLETED
- Phase
- PHASE1
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
FT576 in Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
FT819 in Subjects With B-cell Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
FT538 in Subjects With Advanced Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
- Status
- TERMINATED
- Phase
- PHASE1
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
- Status
- TERMINATED
- Phase
- N/A
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
- Status
- TERMINATED
- Phase
- N/A
FT516 in Subjects With Advanced Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2